Journal of Commercial Biotechnology — January 2010 issue now available

The January 2010 issue of the Journal of Commercial Biotechnology is now available. The links below will take you to the abstract for each paper:

Volume 16, Issue 1

Time for a new business model?	PDF
Yali Friedman

Why data exclusivity is the new patent protection	PDF
Peter J Pitts

Follow-on biologic drug competition – No need for new marketing exclusivities	PDF
Michael S Wroblewski, Elizabeth A Jex

Pharmaceutical royalties in licensing deals: No place for the 25 per cent rule of thumb	PDF
Nigel Borshell, Adrian Dawkes

Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms	PDF
Mark J Ahn, Michael Meeks, Sally Davenport, Rebecca Bednarek

Intellectual property landscape and patenting opportunity in biofuels	PDF
Ramasamy Mannan

Challenges and opportunities in the licensing of renewable technologies	PDF
Meredith Lloyd-Evans, Mike Gilbert, Ilian P Iliev

Ethiopia: Biotechnology for development	PDF
Desta Berhe Sbhatu

Innovation and commercialisation in the stem cell industries in Australia: State strategies and other opportunities to build a competitive position in the global stem cell economy	PDF
Olivia Harvey

Using IP audits to optimize IP assets	PDF
James G Cullem

Book Review: Health-care investing: Profiting from the new world of pharma, biotech and health-care services	PDF
Frank LaSaracina

Book Review: Aging, Biotechnology, and the Future	PDF
Harley King

1 Comment/

January 4, 2010

04 Jan 2010

Drug Patent Expirations in January 2010

*Drugs may be covered by multiple patents

Tradename	Applicant	Generic Name	Patent Number	Patent Expiration
XOPENEX	Sepracor	levalbuterol hydrochloride	6,083,993	Jan 5, 2010
XOPENEX HFA	Sepracor	levalbuterol tartrate	5,844,002	Jan 5, 2010
XOPENEX	Sepracor	levalbuterol hydrochloride	5,844,002	Jan 5, 2010
XOPENEX HFA	Sepracor	levalbuterol tartrate	5,760,090	Jan 5, 2010
XOPENEX HFA	Sepracor	levalbuterol tartrate	6,083,993	Jan 5, 2010
XOPENEX	Sepracor	levalbuterol hydrochloride	5,760,090	Jan 5, 2010
MONOPRIL	Bristol Myers Squibb	fosinopril sodium	5,006,344*PED	Jan 10, 2010
MONOPRIL-HCT	Bristol Myers Squibb	fosinopril sodium; hydrochlorothiazide	5,006,344*PED	Jan 10, 2010
CLARINEX	Schering	desloratadine	5,178,878	Jan 12, 2010
REMERON SOLTAB	Organon Usa Inc	mirtazapine	5,178,878	Jan 12, 2010
ORAPRED ODT	Sciele Pharma Inc	prednisolone sodium phosphate	5,178,878	Jan 12, 2010
FAZACLO ODT	Azur Pharma Intl	clozapine	5,178,878	Jan 12, 2010
ALLEGRA	Sanofi Aventis Us	fexofenadine hydrochloride	5,178,878	Jan 12, 2010
REFLUDAN	Bayer Hlthcare	lepirudin recombinant	5,180,668	Jan 19, 2010
ELMIRON	Ortho Mcneil Janssen	pentosan polysulfate sodium	5,180,715	Jan 19, 2010
VFEND	Pfizer	voriconazole	5,376,645	Jan 23, 2010
GEODON	Pfizer	ziprasidone mesylate	5,376,645	Jan 23, 2010
NEXTERONE	Prism Pharms	amiodarone hydrochloride	5,134,127	Jan 23, 2010
VFEND	Pfizer	voriconazole	5,134,127	Jan 23, 2010
GEODON	Pfizer	ziprasidone mesylate	5,134,127	Jan 23, 2010